ABSTRACT
This chapter presents classification & mode of action, indications & dermatological uses, formulations/presentation, dosages &suggested regimens, baseline investigations, considerations & monitoring, contraindications, cautions, important drug interactions, adverse effects & their management, use in special situations, and essential patient information of Thalidomide. Thalidomide is a derivative of glutamic acid and was first introduced in 1957 as a non-barbiturate sedative hypnotic. Thalidomide is a potent teratogen, and up to 12,000 newborn infants were affected, particularly with phocomelias. Interest in thalidomide and its analogues has re-emerged in recent years as it has significant anti-inflammatory, immunomodulatory and anticancer effects. New analogues of thalidomide, lenolidamide and pomalidomide with greater anti-tumour necrosis factor activity and reduced toxicity have been licensed for use in oncology. Thalidomide is only licensed in Europe for the treatment of multiple myeloma. Thalidomide has been used successfully in children, particularly in actinic prurigo.
